GHK-Cu
A copper-binding tripeptide found naturally in human plasma, studied for skin and tissue repair. The laboratory evidence is deep, and the human trials are small and mostly of facial creams.
How it is offered
Priced With Your Plan
Pricing
Your clinician sets the plan. Pricing is shown before you authorize any charge.
GHK-Cu requires a written prescription from a licensed clinician and is prepared by a licensed pharmacy for an individual patient. Compounded medications are not FDA-approved or evaluated for safety, effectiveness or quality. Evidence standards.
Start Your Assessment →What Is GHK-Cu?
GHK-Cu is the copper-bound form of glycyl-L-histidyl-L-lysine, a small peptide that occurs naturally in human plasma and is released when collagen is broken down. Decades of laboratory work describe effects on collagen, blood vessel growth and gene expression.
The human literature is thin and fragmented: most randomized trials are small and were done with facial cosmetic creams. A 2026 systematic review notes that microneedle delivery has not yet been tested in an adequately powered human trial, and that the human literature it reviewed is mostly facial creams.
Good to Know
- Prescribed only after a clinician reviews your history.
- Dose and course are set by your clinician, not by you.
- Results vary, and we do not promise outcomes.
Who It Is For
Eligibility
Competitive Athletes
Many peptides are prohibited in sport, or fall under rules that change. A prescription does not establish sporting eligibility, so we ask about anti-doping rules before presenting any option.
Often a Good Fit If
- ✓Interested in skin quality or tissue repair and comfortable with limited human evidence
- ✓Willing to complete a baseline visit and a defined course
- ✓Aware that topical and injected products are different things
- ✓Open to stopping if there is no measurable or subjective benefit
Not Prescribed If
- —Pregnancy, breastfeeding, or actively trying to conceive
- —Active or recent cancer diagnosis, or a history your clinician judges to carry risk
- —Expecting a guaranteed or fast outcome rather than a considered trial
- —Wilson disease or any condition affecting copper handling
- —Prior serious hypersensitivity to GHK-Cu or its excipients
Read Before You Decide
Key Risks, Stated Plainly
There is no established safety record for injected GHK-Cu in controlled human trials. Because it is a copper complex, anyone with a condition affecting copper handling is excluded. GHK-Cu is proposed to influence blood vessel growth and gene expression in laboratory work, which is a theoretical reason for caution in anyone with a cancer history.
Contact care the same day for
Significant swelling or pain at an injection site, signs of allergic reaction, or any new or unexplained symptom during a course.
What Is Measured
Baseline Photos and Notes
A dated baseline, so any change is compared against it and not memory.
Injection-Site Tolerance
Reviewed early, when most reactions appear.
Your Own Goal Measure
One simple measure of what you hope to change, rated at each check-in.
Course Endpoint
A scheduled reassessment against your original goal.
A Clearer Path Forward
How Clinicians Review Your Response
You and Your Clinician Look at the Same Data
Symptoms you report, laboratory results and, if you connect one, wearable trends are reviewed together before any change.
A Physician-Led Review Every 90 Days
Included in your monthly price. Your clinician decides whether to continue, adjust the dose, change course or stop.
Clinical Judgment Decides
Measurements inform the decision. They do not make it, and no dashboard changes your dose on its own.
Your Care Sequence
01
Questionnaire
Share your goals, history and any sport or work rules in about ten minutes. No card required.
02
Video Visit
Your clinician reviews your history and medications, explains the evidence plainly, and decides whether this fits you.
03
Delivery
If prescribed, medication ships from a licensed pharmacy with supplies and written instructions.
04
Reassessment
A scheduled review decides whether to stop, extend or change course. Courses are not renewed by default.
Common Questions About GHK-Cu
Does GHK-Cu Work for Skin?+
A 2026 systematic review found the preclinical evidence deep but the human literature thin, with small randomized trials mostly of facial creams. We do not claim a skin benefit from injection.
What Is Its FDA Status?+
GHK-Cu appears on FDA's May 14, 2026 Category 1 list except injectable routes. Category 1 is an interim compounding-policy classification, not an approval and not proof of efficacy.
Is the Copper a Concern?+
For most people the amount is small, but anyone with Wilson disease or another copper-handling condition is excluded, and we review your history first.
How Is It Different From a Copper Peptide Cream?+
Creams are cosmetic products with small trials behind them. Injected GHK-Cu is a different route with far less human evidence.
Is It Available Through SOVRYN?+
GHK-Cu is prescribed only after a clinician reviews your history and decides it fits. Start with the assessment and your clinician will tell you what is and is not appropriate.
Still unsure? Message the care team before you join. No account needed.
Published Research
What the Published Science Shows
40+ yrs
Of preclinical evidence on GHK-Cu described in a 2026 systematic review.
64
Records synthesized from 1,247 screened in that review, which found the human literature thin and fragmented.
0
Adequately powered randomized trials of microneedle-delivered GHK-Cu found in that review.
Figures come from the cited trials and reviews. They describe published research, not a forecast for any one person, and not a study of compounded formulations.
The Mechanism
The Proposed Mechanism
Matrix Signaling
It is proposed to influence collagen, elastin and glycosaminoglycan synthesis by dermal fibroblasts.
Gene Regulation
Gene-expression data suggest it regulates many pathways, which may explain its diverse effects in the lab.
Copper Cofactor
Copper is a cofactor for enzymes that cross-link collagen and elastin.
For Readers Who Want More
Deeper Evidence
What We Can and Cannot Tell YouEvidence and regulatory status+
What the Evidence Supports
Consistent laboratory and animal findings on collagen synthesis, blood vessel and nerve outgrowth and tissue repair, and small human trials of topical use on skin appearance.
What It Does Not (Yet)
No adequately powered human trials of injected or microneedle-delivered GHK-Cu, and no established efficacy by injection.
Badge definitions and FDA category sourcing are on the Science page.
Illustrative Course StructureFinal dose set by your clinician+
Illustrative only and not a prescription. Dose, timing and length are set by your clinician and the compounding pharmacy.
| Phase | Approach | Duration | What We Watch |
|---|---|---|---|
| Baseline | Visit, labs where indicated | Before starting | Symptoms, relevant labs |
| Course | Clinician-set dose, held at the tolerated level | Defined by your clinician | Tolerance, response |
| Reassessment | Extend, stop or change course | At the scheduled review | Whether the goal was met |
Selected Studies
Pickart and Margolina, International Journal of Molecular Sciences, 2018 (review of GHK-Cu)
Reviews decades of mostly laboratory work on the GHK peptide: effects on collagen and elastin synthesis, blood vessel and nerve outgrowth, and gene expression. It is a review, not a clinical trial.
Read the Source ↗Najafi et al., 2026 (PMID 42787770), systematic review of GHK-Cu
After screening 1,247 records, 64 were synthesized. The authors conclude the preclinical evidence is deep but the human literature is thin and fragmented, with small trials mostly of facial creams.
Read the Source ↗Renke and Chinellato, International Journal of Molecular Sciences, 2026 (review of 106 articles)
Reviewed the effects, safety and regulatory status of prominent therapeutic peptides, including unapproved ones, and concluded that further studies are needed before most new peptides can be used safely in humans.
Read the Source ↗Often Considered Together
Paired With
Start Your Assessment for Skin and Tissue Options
Ten minutes, no card, reviewed by a clinician.